secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097001
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M
--------------------------------------------------------------------------------

- ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.
- CNSide diagnostic met primary endpoint: helped clinical decisions in >90% of cases; tumor cell detection 80% vs 29% cytology.
- Received $3.3M CPRIT grant in June 2024 for Rhenium (186Re) Obisbemeda development.
- Cash $8.4M at June 30; H1 net loss $6.2M ($1.15/share) vs $6.3M ($2.60/share) year ago.
- Upcoming: complete ReSPECT-LM Phase 1 single-dose, initiate multiple-dose Phase 1, and IND for pediatric trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/0000950170-24-097001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/pstv-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer